Samsung Biologics will provide large-scale commercial manufacturing for drug substance at its Plant 3 site in South Korea. Situated in Songdo, Incheon, the facility was opened in 2018 and is the world’s largest single bio manufacturing plant.
The South Korean CDMO will also provide drug product to support AstraZeneca’s biologics therapeutics.
The agreement could be expanded to $545.6m.
In partnering with Samsung Biologics, AstraZeneca will be able to expand its biologics manufacturing capabilities in Asia Pacific. The agreement is also expected to accelerate Korean bio-health innovation, according to the two companies.
Pam Cheng, EVP Global Operations & IT, AstraZeneca, said: "This long-term partnership with Samsung Biologics strengthens our manufacturing capabilities, and ensures we are well-positioned to continue to deliver our exciting portfolio of new and established biologics medicines to patients with quality, speed and efficiency.”
Dr. Tae Han Kim, CEO of Samsung Biologics, said: "We are very proud to partner with AstraZeneca, a company that uses a rich history of science-led innovation to serve patients. At Samsung Biologics, our people share this common purpose to help our clients bring innovative solutions to an array of diseases, and we look forward to delivering on our promise to aid in AstraZeneca's ongoing expansion program."